Published in
American Society of Hematology, Blood, 16(129), p. 2246-2256
DOI: 10.1182/blood-2016-09-738211
Links
Tools
Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity
Journal article published in 2017 by
Shruti Bhatt,
Salma Parvin,
Yu Zhang,
Hyun-Mi Cho,
Kranthi Kunkalla,
Francisco Vega 
,
John M. Timmerman,
Seung-Uon Shin,
Joseph D. Rosenblatt,
Izidore S. Lossos
,
John M. Timmerman,
Seung-Uon Shin,
Joseph D. Rosenblatt,
Izidore S. Lossos
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Delivering IL-21 to tumor B cells by fusion with anti-CD20 antibody (αCD20-IL-21 fusokine) is a potent antilymphoma therapeutic strategy. αCD20-IL-21 fusokine demonstrated superior antilymphoma activity compared with its individual components.